LI VING WELL WI TH HEM OPHI LI A

We had a great turnout for the First Step program held in August at the Children’s Museum in Pittsburgh! The room was full to capacity with families with young children who wanted to learn more about hemophilia.

Cathy Tiggs, a social worker at University Hospital in Cleveland, presented Living Well with Hemophilia. Her presentation included genetic information, recognizing and addressing different types of bleeds, and staying healthy to avoid potential complications. Cathy engaged the audience and had participation from people of all ages. We were very impressed with how much some of the children already knew about their bleeding disorders! This wonderful program was sponsored by Novo Nordisk.

First Step programs are offered for families with children ages 0-8 who have a bleeding disorder. In addition to educational programs, families can be matched up with an experienced mentor family. If you are interested in being matched with a mentor or would like to make a suggestion for a future program, please contact Janet Barone, Member Services Manager, at the Chapter office or Kathaleen Schnur, Social Worker, at the Hemophilia Center of Western PA.

WALK AND RUN FOR THEIR LIVES 5K

A Great Success!
Despite another year of rain, the 2014 Western Pennsylvania Hemophilia Walk and Run For Their Lives 5K were a huge success! Over 400 walkers and 115 runners successfully raised over $60,000 to help those affected by bleeding disorders. Walk day activities included a moon bounce obstacle course, Velcro wall, face paint artist, and balloon artist. The gift baskets included goodies for the entire family! Money raised

(Continued on page 15)
Camp Hot-to-Clot 2014 – Campers vs. Wild

By Kathaleen Schnur

Camp-Hot-to-Clot 2014 welcomed the campers to challenge the wild and ended with our campers triumphantly, albeit exhausted, conquering the wild. During this sun up to sun down, fast paced, fun, and educational week, our campers learned about playing it safe while participating in different activities. On Monday, the campers learned about being resourceful in the wild to address medical or emergency situations, build fires, and construct a shelter. Tuesday the campers participated in service projects which were later shared with local groups. A special treat on Tuesday evening included the Wild World of Animals show which educated campers on various wild animals including a Red Tailed Hawk, a Snow Linx, and even a Boa Constrictor! After the wild animal show, the campers made a survival bracelet that in an emergency can be taken apart and used for tying things together or even fishing. Wednesday the campers spent much time (and bravery) on the high ropes, low ropes, zip lines, and climbing walls. In Camp Hot-to-Clot tradition, Wednesday night was carnival night! Many games, much laughter, a dunk tank, “photo booth,” water balloons, and even a flavored shaved ice truck tired everyone out!

Amidst all the above excitement, the campers participated in the traditional camp activities such as boating, swimming, archery, fishing, creek stomping, gaga pit, crafts, and bon fires with s’mores. Every evening brought the reward of pizza to the group of campers with the cleanest cabin. Thursday and Friday were full of camaraderie as many of the campers attempted and successfully learned to infuse themselves. There was much “Sticking Together” happening as well for those campers who don’t infuse with Factor, but learned the process of self-infusion to stand in solidarity with their siblings and friends.

Thursday evening the campers learned survival skills were put to the test in a camp wide challenge. Each group was given 30 minutes at each station where they had to build a functional raft, build a fire that burned hot enough and high enough to boil water, and navigate a maze without touching the walls. This was a fantastic way to bond with each other and test our skills.

Amidst all the above excitement, the campers participated in the traditional camp activities such as boating, swimming, archery, fishing, creek stomping, gaga pit, crafts, and bon fires with s’mores. Every evening brought the reward of pizza to the group of campers with the cleanest cabin. Thursday and Friday were full of camaraderie as many of the campers attempted and successfully learned to infuse themselves. There was much “Sticking Together” happening as well for those campers who don’t infuse with Factor, but learned the process of self-infusion to stand in solidarity with their siblings and friends.

Thursday evening the campers learned survival skills were put to the test in a camp wide challenge. Each group was given 30 minutes at each station where they had to build a functional raft, build a fire that burned hot enough and high enough to boil water, and navigate a maze without touching the walls. This was a fantastic way to bond with each other and test our skills.

(Continued on page 15)
Letter From The President, Scott Miller

Dear Members, Friends, and Supporters,

This has certainly been a busy start to the 2014-15 year! Our Annual Meeting, Camp Hot-to-Clot, the Walk and 5k Run for Their Lives, as well as NHF’s Annual Meeting in Washington, DC. The staff has done a fantastic job preparing for our Fall events. If you look at the event calendar, you will see so many excellent programs scheduled. I hope that you take advantage of some these opportunities.

I want to thank all of those who participated in the Walk and Run for Their Lives. The money raised will ensure that we can continue our efforts in meeting our mission and providing you with educational programming and other resources to improve the lives of our members – including taking TEN families to the NHF Annual Meeting in Washington, DC! Due to its relatively close location, we were able to extend additional scholarships to this meeting this year and we had a great showing from Western Pennsylvania! You will also see information in this newsletter about Take A Bough, one of our signature events. This year, the event is moving to One Oxford Centre, one of the largest office buildings in downtown Pittsburgh, which is an amazing opportunity. This event is not only a fundraiser for our chapter, but provides awareness to the Pittsburgh and surrounding community about bleeding disorders and the Chapter’s services. Having the event at one Oxford Centre will increase awareness among the business community in Pittsburgh and be great exposure for our Chapter.

I look forward to seeing you and your family at our upcoming events. As always, please don’t hesitate to contact me, or the Chapter staff, if you have any questions or concerns.

Sincerely,

Scott E. Miller, CPA, J.D., DBA
WPCNHF Board President

Dear Members, Friends, and Supporters,

This has certainly been a busy start to the 2014-15 year! Our Annual Meeting, Camp Hot-to-Clot, the Walk and 5k Run for Their Lives, as well as NHF’s Annual Meeting in Washington, DC. The staff has done a fantastic job preparing for our Fall events. If you look at the event calendar, you will see so many excellent programs scheduled. I hope that you take advantage of some these opportunities.

I want to thank all of those who participated in the Walk and Run for Their Lives. The money raised will ensure that we can continue our efforts in meeting our mission and providing you with educational programming and other resources to improve the lives of our members – including taking TEN families to the NHF Annual Meeting in Washington, DC! Due to its relatively close location, we were able to extend additional scholarships to this meeting this year and we had a great showing from Western Pennsylvania! You will also see information in this newsletter about Take A Bough, one of our signature events. This year, the event is moving to One Oxford Centre, one of the largest office buildings in downtown Pittsburgh, which is an amazing opportunity. This event is not only a fundraiser for our chapter, but provides awareness to the Pittsburgh and surrounding community about bleeding disorders and the Chapter’s services. Having the event at one Oxford Centre will increase awareness among the business community in Pittsburgh and be great exposure for our Chapter.

I look forward to seeing you and your family at our upcoming events. As always, please don’t hesitate to contact me, or the Chapter staff, if you have any questions or concerns.

Sincerely,

Alison Yazer
Executive Director

Letter From The Executive Director, Alison Yazer

Greetings!

I can’t believe how quickly time has flown by as I start my third year with the Chapter!

We always strive to provide a variety of interesting, informative educational sessions – each of which also has a social aspect to it. Whether it’s going to the movies after the Annual Meeting or attending a baseball game after Men’s and Women’s groups, we understand how important the friendships you build with other members are, so we do everything we can to help build networking opportunities into each and every event.

Please check the calendar for upcoming events – there are lots of them! They include educational events in Erie, Pittsburgh, Greensburg and more! The fifth annual Take A Bough will be November 19th – 22nd and this year it’s moving to One Oxford Centre downtown. I hope you and your family will join us for one or more of these great events!

As always, please contact the Chapter with any questions or concerns. Thank you for all that you do on behalf of WPCNHF.

Sincerely,

Alison Yazer
Executive Director

WPCNHF Scholarship Winner

Congratulations to Nikole Scappe winner of the 2014-2015 WPCNHF Scholarship! Nikole is a student at LaRoche College, where she has a double major in Marketing and Management.
Calendar of Upcoming Events

Wednesday, October 15
Women's Group - Communications with Your Health Care Provider
Wexford, PA

Tuesday, October 28
Backyard Advocacy
Erie, PA

Wednesday, October 29
Backyard Advocacy
Greensburg, PA

Wednesday, November 12
Emotional Well-being in the Hemophilia Community
Indiana, PA

Thursday, November 13
Emotional Well-being in the Hemophilia Community
Robinson Township, PA

Wednesday, November 19 – Saturday, November 22
Take A Bough
Oxford Centre, Pittsburgh, PA

Winterfest: TBA

Combined Federal Campaign
WPCNHF is an approved charitable organization for the Combined Federal Campaign (CFC). If you participate in the CFC, please consider designating all or a portion of your donation to the Chapter.

WPCNHF CFC Number is: 81343

Ask us about sponsorship opportunities and how you can help!
Researchers Report Advances in Plant-Based Hemophilia A Therapy

A team of researchers from the University of Florida, Gainesville (UF-G) and University of Pennsylvania (U-Penn) is developing a novel approach to tackling inhibitors in hemophilia A that uses genetically engineered plant cells. In a recent article published in the journal Blood, the authors reported making progress with the experimental therapy in mice with hemophilia A. The lead investigator of the study was Henry Daniell, PhD, Department of Biochemistry and Department of Pathology, School of Dental Medicine at U-Penn in Philadelphia.

Using genetically engineered plants, Daniell and his colleagues are developing therapeutic factor proteins that decrease unwanted treatment reactions such as anaphylaxis (a life-threatening allergic reaction) and inhibitor (antibody) responses by the immune system. The technique involves encapsulating a “tolerance-inducing protein” within plant cell walls so that when it is ingested it safely travels through the stomach before being released into the small intestines. In this study, investigators synthesized tobacco plants and factor VIII-coded genetic material, which were fed to mice with hemophilia A. The therapy triggered an average of seven times fewer inhibitor responses. “This is a major step forward,” said study co-author Roland W. Herzog, PhD, College of Medicine, UF-G. In the future, the goal is to replace tobacco plants with lettuce plants for human use.

Researchers have been developing this novel therapeutic approach for several years to create potential vaccines against malaria and cholera, and genetically engineered insulin to help prevent diabetes. In previous studies led by Daniell, factor IX-bioencapsulated plant cells were successfully delivered to mice with hemophilia B. The therapy prevented both anaphylaxis and inhibitors.

The authors see a tremendous upside if this oral tolerance therapy were to become a viable option for humans. “Our technique, which uses plant-based capsules, has the potential to be a cost-effective and safe alternative,” said Daniell.


Source: newKerala.com, September 4, 2014

If You Have Hemophilia, Your Female Relatives May Need Your Help!

If you have hemophilia, some of your female relatives may be carriers of hemophilia. Being a carrier can impact a female's own health and management. It can also provide valuable information for that female's children and other family members. Ultimately, this piece of information can lead to fewer health complications for carriers of hemophilia and their children. Even if your female relatives know that they have a chance to be a carrier, they may not know who to ask for more information or where to go to find out if they are a carrier or not. They may need your help!

The Hemophilia Center of Western Pennsylvania (HCWP) is here to support our patients and their families. Our staff is uniquely positioned to help your female relatives understand their chance to be a carrier and to help them figure out their carrier status, if interested. Please share this information with your female relatives. It could drastically impact their lives.

If you are a female relative of someone with hemophilia or are interested in more information, please contact Michelle Alabek, HCWP genetic counselor, at 412-209-7292.
ADVATE PROPHYLAXIS MAY HELP YOU PREVENT OR REDUCE THE FREQUENCY OF BLEEDS

SIGNIFICANT REDUCTION IN MEDIAN ANNUAL BLEED RATE (ABR) WITH PROPHYLACTIC TREATMENT COMPARED WITH ON-DEMAND TREATMENT

• 42% of patients experienced 0 bleeds during 1 year on prophylaxis
• 98% reduction in median ABR from 44 to 1 when switched from on-demand to prophylaxis

In a clinical study, after switching from 6 months of on-demand treatment to 12 months of prophylaxis with ADVATE in 53 previously treated patients (PTPs) with severe or moderately severe hemophilia A.

A clinical study that evaluated treatment efficacy (the ability to control and reduce bleeds) of 2 prophylaxis regimens—Every-Second-Day (standard) prophylaxis dosed at 20 to 40 IU/kg every 48 hours and Every-Third-Day (pharmacokinetic-driven) prophylaxis dosed at 20 to 80 IU/kg every 72 hours, targeted to maintain factor VIII trough levels ≥1%.

INDICATIONS

ADVATE is a medicine used to replace clotting factor VIII that is missing in people with hemophilia A (also called “classic” hemophilia). ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A. Your healthcare provider may give you ADVATE when you have surgery. ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand Disease.

DETAILED IMPORTANT RISK INFORMATION

You should not use ADVATE if you:

• Are allergic to mice or hamsters.
• Are allergic to any ingredients in ADVATE.

Tell your healthcare provider if you are pregnant or breastfeeding because ADVATE may not be right for you.

You should tell your healthcare provider if you:

• Have or have had any medical problems.
• Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
• Have any allergies, including allergies to mice or hamsters.
• Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

Your body may form inhibitors to factor VIII. An inhibitor is part of the body’s normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

You can have an allergic reaction to ADVATE.

Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.

Side effects that have been reported with ADVATE include cough, headache, joint swelling/aching, sore throat, fever, itching, unusual taste, dizziness, hematoma, abdominal pain, hot flashes, swelling of legs, diarrhea, chills, runny nose/congestion, nausea/vomiting, sweating, and rash.

Tell your healthcare provider about any side effects that bother you or do not go away or if your bleeding does not stop after taking ADVATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Brief Summary of ADVATE Prescribing Information on the following page.

Reference:

Baxter and Advate are registered trademarks of Baxter International Inc. All rights reserved. USBS/34/14-0090
Symptoms include dizziness, paresthesia, rash, flushing, facial swelling, urticaria, dyspnea, and pruritus. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with ADVATE.

WARRANTINGS AND PRECAUTIONS

Hypersensitivity Reactions

Allergic-type hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product (mannitol, trehalose, sodium chloride, histidine, Tris, calcium chloride, polylorbose 80, and/or glycoluril).

Neutralizing Antibodies

Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (PMTs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose of ADVATE, use Bethesda Units (BU) to titer inhibitors.

Monitoring Laboratory Tests

- Monitor plasma factor VIII activity levels by the one-stage clotting assay to confirm the adequate factor VIII levels have been achieved and maintained when clinically indicated. (see Dosage and Administration)
- Perform the Bethesda assay to determine if factor VIII inhibitor is present. If expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with the expected dose of ADVATE, use Bethesda Units (BU) to titer inhibitors.

ADVERSE REACTIONS

The serious adverse reactions seen with ADVATE are hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to factor VIII.

The most common adverse reactions observed in clinical trials (frequency >10% of subjects) were pyrexia, headache, cough, nasopharyngitis, vomiting, arthralgia, and limb injury.

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.

ADVATE has been evaluated in five completed clinical trials in previously treated patients (PTPs) and one ongoing trial in previously untreated patients (PUPs) with severe to moderately severe hemophilia A (factor VIII ≤2% of normal). A total of 234 subjects have been treated with ADVATE as of March 2006. No subjects were withdrawn from a clinical trial due to an adverse reaction. There were no deaths in any of the clinical trials.

### Table 3

<table>
<thead>
<tr>
<th>MedDRA$^a$ System Organ Class</th>
<th>MedDRA Preferred Term</th>
<th>Number of ADRs</th>
<th>Number of Subjects</th>
<th>Percent of Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>General disorders and administration site conditions</td>
<td>Pyrexia</td>
<td>78</td>
<td>50</td>
<td>21</td>
</tr>
<tr>
<td>Neurological disorders</td>
<td>Headache</td>
<td>104</td>
<td>49</td>
<td>21</td>
</tr>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td>Cough</td>
<td>75</td>
<td>44</td>
<td>19</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Nasopharyngitis</td>
<td>61</td>
<td>40</td>
<td>17</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Vomiting</td>
<td>35</td>
<td>27</td>
<td>12</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia</td>
<td>44</td>
<td>27</td>
<td>12</td>
</tr>
<tr>
<td>Injury, poisoning, and procedural complications</td>
<td>Limb injury</td>
<td>55</td>
<td>24</td>
<td>10</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Upper respiratory tract infection</td>
<td>24</td>
<td>20</td>
<td>9</td>
</tr>
</tbody>
</table>

Respiratory, thoracic, and mediastinal disorders

Blood and lymphatic system disorders

Immunologic disorders

Table 4

<table>
<thead>
<tr>
<th>Organ System (MedDRA Primary SOC)</th>
<th>Preferred Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td>Anaphylactic reaction$^a$, Hypersensitivity$^a$</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Factor VIII inhibition</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Injection site reaction</td>
</tr>
<tr>
<td>Other</td>
<td>Chest discomfort/pain</td>
</tr>
</tbody>
</table>

- $^a$ These reactions have been manifested by dizziness, paresthesias, rash, flushing, face swelling, urticaria, and/or pruritus.

Baxter, and Advate are trademarks of Baxter International Inc. Baxter and Advate are registered in the U.S. Patent and Trademark Office. Patented: see www.baxter.com/productpatents/

Baxter Healthcare Corporation, Westlake Village, CA 91362 USA

U.S. License No. 140 Issued 04/2014

US33/24/14-0104

$^a$ MedDRA version 8.1 was used.

Immune reactivity also was evaluated by measuring the development of antibodies to heterologous proteins. 182 treated subjects were assessed for anti-Chinese hamster ovary (CHO) cell protein antibodies. Of these subjects, 3 showed an upward trend in antibody titer over time and 4 showed repeated but transient elevations of antibodies. 182 treated subjects were assessed for mumps protein antibodies. Of these, 10 showed an upward trend in anti-mumps antibody titer over time and 2 showed repeated but transient elevations of antibodies. Four subjects who demonstrated antibody elevations reported isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil counts. All of these subjects had numerous repeat exposures to the study product without recurrence of the events and a causal relationship between the antibody findings and these clinical events had not been established.

The 181 subjects who were treated and assessed for the presence of anti-human von Willebrand Factor (vWF) antibodies, none displayed laboratory evidence indicative of a positive serologic response. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ADVATE with the incidence of antibodies to other products may be misleading.

Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of ADVATE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Among patients treated with ADVATE, cases of serious allergic/hypersensitivity reactions including anaphylaxis have been reported and factor VIII inhibitor formation (observed predominantly in PUPs).
Spotlight on the Member: Brendon Simpson

Hemophilia has been in Brendon Simpson’s family for at least three generations. The first family member to be diagnosed was Brendon’s grandfather. His grandfather was born in the 1910’s. Growing up, his grandfather had a number of issues with bleeds, but no one knew what the cause was. He was able to manage his bleeds until he had a tooth extracted sometime in the mid 1940’s. He was hospitalized and bled for days. Although many people were willing to donate blood, he had a rare blood type. A few days into his hospital stay, a doctor spotted his grandmother crying in the waiting room and stopped to talk with her. When he heard her story, he donated blood and his blood type was a match! Although he still didn’t have a diagnosis, his grandfather’s bleeding stopped after he received the blood transfusion. It wouldn’t be until many years later that he would receive a diagnosis.

By the time Brendon was born, his older brother had been diagnosed with Hemophilia after experiencing a number of bleeding episodes. So Brendon was tested at birth and was diagnosed with severe hemophilia A. Brendon recalls long days at the blood bank being treated with cryoprecipitate, when he was a child.

Although Brendon and his brother had the same diagnosis, Brendon’s bleeds did not occur as frequently nor did they stay active as long as his brother’s bleeds. His brother had frequent, heavy nose bleeds, and fortunately, Brendon did not. As with many people with bleeding disorders, though, he would occasionally have a mouth bleed which were always a challenge to control. Fortunately, he did not get them often, either.

Brendon’s parents were cautious with their children; however, they did their best not to hold them back from having many of the same experiences as children without bleeding disorders. Although Brendon didn’t participate in team sports, he did play catch, tag football, and street hockey with his friends and over time, he learned his limits. Today he enjoys bowling, spending time on the driving range hitting golf balls, and playing deck hockey.

Brendon has been a long time member of the Chapter and he particularly enjoys participating in the Hemophilia Walk. He says it’s a great way to get a little exercise and some fresh air and he likes that it brings people together for a great purpose! As long as his ankles are feeling good, he makes it a point to attend the Walk.

Brendon has also served on the Consumer Advocacy Committee for the Hemophilia Center of Western PA for the past seven years. He takes his role seriously. He feels that he represents adults with hemophilia and he offers opinions and raises concerns on their

(Continued on page 15)
Now Available

A new treatment for hemophilia B

ALPROLIX provides protection* from bleeds starting with at least a week between prophylaxis infusions.

Dosing regimen can be adjusted based on individual response.

*Protection is the prevention of bleeding episodes using a prophylaxis regimen.

To learn more, contact CoRe Manager Christine Rowe
E: christine.rowe@biogenidec.com  T: 267.249.8372

Indications and Important Safety Information

Indications
ALPROLIX, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived, coagulation factor IX concentrate indicated in adults and children with hemophilia B for:

- Control and prevention of bleeding episodes
- Perioperative management
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Important Safety Information
Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to factor IX.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called “inhibitors” against ALPROLIX, which may stop ALPROLIX from working properly.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing clots.

Common side effects of ALPROLIX include headache and abnormal sensation of the mouth. These are not all the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, and if bleeding is not controlled using ALPROLIX.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Brief Summary of full Prescribing Information on the next page. This information is not intended to replace discussions with your healthcare provider.

biogen idec. © 2014 Biogen Idec. All rights reserved. Printed in U.S.A. 5/16 FIX-1005139
ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], Lyophilized Powder for Solution For Intravenous Injection.

FDA Approved Patient Information

ALPROLIX™ /əlˈprɔ liks/ [Coagulation Factor IX (Recombinant), Fc Fusion Protein]

Please read this Patient Information carefully before using ALPROLIX™ and each time you get a refill, as there may be new information. This Patient Information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is ALPROLIX™?

ALPROLIX™ is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency.

Your healthcare provider may give you ALPROLIX™ when you have surgery.

Who should not use ALPROLIX™?

You should not use ALPROLIX™ if you are allergic to ALPROLIX™ or any of the other ingredients in ALPROLIX™. Tell your healthcare provider if you have had an allergic reaction to any Factor IX product prior to using ALPROLIX™.

What should I tell my healthcare provider before using ALPROLIX™?

Tell your healthcare provider about all of the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal medicines. Tell your doctor about all of your medical conditions, including if you:

- are pregnant or planning to become pregnant. It is not known if ALPROLIX™ may harm your unborn baby.
- are breastfeeding. It is not known if ALPROLIX™ passes into breast milk or if it can harm your baby.
- have been told that you have inhibitors to Factor IX (because ALPROLIX™ may not work for you).

How should I use ALPROLIX™?

ALPROLIX™ should be administered as ordered by your healthcare provider. You should be trained on how to do infusions by your healthcare provider. Many people with hemophilia B learn to infuse their ALPROLIX™ by themselves or with the help of a family member.

See the Instructions for Use for directions on infusing ALPROLIX™. The steps in the Instructions for Use are general guidelines for using ALPROLIX™. Always follow any specific instructions from your healthcare provider. If you are unsure of the procedure, please ask your healthcare provider. Do not use ALPROLIX™ as a continuous intravenous infusion.

Contact your healthcare provider immediately if bleeding is not controlled after using ALPROLIX™.

What are the possible side effects of ALPROLIX™?

Common side effects of ALPROLIX™ include headache and abnormal sensation in the mouth.

Allergic reactions may occur. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

ALPROLIX™ may increase the risk of forming abnormal blood clots in your body, especially if you have risk factors for developing blood clots.

Your body can also make antibodies called, “inhibitors,” against ALPROLIX™, which may stop ALPROLIX™ from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time. These are not all the possible side effects of ALPROLIX™.

Talk to your healthcare provider about any side effect that bothers you or that does not go away.

How should I store ALPROLIX™?

Store ALPROLIX™ vials at 2°C to 8°C (36°F to 46°F). Do not freeze.

ALPROLIX™ vials may also be stored at room temperature up to 30°C (86°F) for a single 6 month period.

If you choose to store ALPROLIX™ at room temperature:

- Note on the carton the date on which the product was removed from refrigeration.
- Use the product before the end of this 6 month period or discard it.
- Do not return the product to the refrigerator.

Do not use product or diluent after the expiration date printed on the carton, vial or syringe.

After Reconstitution:

- Use the reconstituted product as soon as possible; however, you may store the reconstituted product at room temperature up to 30°C (86°F) for up to 3 hours. Protect the reconstituted product from direct sunlight. Discard any product not used within 3 hours after reconstitution.
- Do not use ALPROLIX™ if the reconstituted solution is cloudy, contains particles or is not colorless.

What else should I know about ALPROLIX™?

Medicines are sometimes prescribed for purposes other than those listed here. Do not use ALPROLIX™ for a condition for which it was not prescribed. Do not share ALPROLIX™ with other people, even if they have the same symptoms that you have.

Manufactured by
Biogen Idec Inc.
14 Cambridge Center
Cambridge, MA 02142
U.S. License #1697
ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is now available in a 2000 IU FVIII vial with a reconstitution volume of only 10 mL.

*That’s TWICE the amount of factor of the largest vial available for other FVIII/VWF products,¹ ² ³ ⁴ so patients may require:

- Less volume
- Less time
- Fewer syringes

Isn’t it time you tried ALPHANATE?

Indications
ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

- Control and prevention of bleeding in patients with hemophilia A
- Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP®) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery

Important Safety Information
ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible. Should symptoms occur, treatment with ALPHANATE should be discontinued, and emergency treatment should be sought.

Development of activity-neutralizing antibodies has been detected in patients receiving FVIII containing products. Development of alloantibodies to VWF in Type 3 von Willebrand disease (VWD) patients has been occasionally reported in the literature.

Thromboembolic events may be associated with AHF/VWF Complex (Human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may be associated with infusion of massive doses of AHF/VWF Complex (Human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

The most frequent adverse events reported with ALPHANATE in >5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain, and fatigue.

Please see brief summary of ALPHANATE full Prescribing Information on adjacent page.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
ALPHANATE®
Antihemophilic Factor/von Willebrand Factor Complex (Human)

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use Alphanate safely and effectively. See full prescribing information for Alphanate.

ALPHANATE (ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX [HUMAN])
Sterile, lyophilized powder for injection.
Initial U.S. Approval: 1978

--INDICATIONS AND USAGE--
Alphanate is an Antihemophilic Factor/von Willebrand Factor Complex (Human) indicated for:
• Control and prevention of bleeding in patients with hemophilia A.
• Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand Disease in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery.

--DOSAGE AND ADMINISTRATION--
For Intravenous use only.
Alphanate contains the labeled amount of Factor VIII expressed in International Units (IU) FVIII/vial and von Willebrand Factor:Ristocetin Cofactor activity in IU VWF:RCo/vial.

Hemophilia A: Control and prevention of bleeding episodes
• Dose (units) = body weight (kg) x desired FVIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL).
• Frequency of intravenous injection of the reconstituted product is determined by the type of bleeding episode and the recommendation of the treating physician.

von Willebrand Disease: Surgical and/or invasive procedure in adult and pediatric patients except Type 3 undergoing major surgery
• Adults: Pre-operative dose of 60 IU VWF:RCo/kg body weight; subsequent doses of 40-60 IU VWF:RCo/kg body weight at 8-12 hour intervals post-operative as clinically needed.
• Pediatric: Pre-operative dose of 75 IU VWF:RCo/kg body weight; subsequent doses of 50-75 IU VWF:RCo/kg body weight at 8-12 hour intervals post-operative as clinically needed.

--DOSAGE FORMS AND STRENGTHS--
• Alphanate is a sterile, lyophilized powder for intravenous injection after reconstitution, available as 250, 500, 1000, 1500 and 2000 IU FVIII in single dose vials.

--CONTRAINDICATIONS--
• Patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

--WARNINGS AND PRECAUTIONS--
• Anaphylaxis and severe hypersensitivity reactions are possible. Should symptoms occur, treatment with Alphanate should be discontinued, and emergency treatment should be sought.
• Development of activity-neutralizing antibodies has been detected in patients receiving FVIII containing products. Development of alloantibodies to VWF in Type 3 VWD patients has been occasionally reported in the literature.
• Thromboembolic events may be associated with AHF/VWF Complex (Human) in VWD patients, especially in the setting of known risk factors.
• Intravascular hemolysis may be associated with infusion of massive doses of AHF/VWF Complex (Human).
• Rapid administration of a FVIII concentrate may result in vasomotor reactions.
• Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

--ADVERSE REACTIONS--
The most frequent adverse events reported with Alphanate in > 5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain and fatigue.

To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals Inc. at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

--USE IN SPECIFIC POPULATIONS--
• Pregnancy: No human or animal data. Use only if clearly needed.
• Pediatric Use: Hemophilia A - Clinical trials for safety and effectiveness have not been conducted. VWD - Age had no effect on PK.

GRIFOLS
Grifols Biologicals Inc.
5555 Valley Boulevard
Los Angeles, CA 90032, U.S.A.
U.S. License No. 1694
3041048-BS
Revised: 06/2014
Board of Directors

President
Scott Miller, CPA, Esq.

Vice President
Nathan Rost

Treasurer
Nick Vizzoca

Secretary
Mike Covert

Director
Jen Smith

Directors Emeriti
Jim Loll
Missy Unkovic

Staff

Executive Director
Alison Yazer

Member Services Manager
Janet Barone

Bookkeeper & Office Assistant
Kara Dornish

Fundraising & Events Manager
Brittani Reed

Staff office hours are Monday through Friday from 9 a.m. until 4 p.m. Every attempt will be made to return calls received during regular office hours on the same day.

Our Mission:
The Western Pennsylvania Chapter of the National Hemophilia Foundation is leading the way in Western Pennsylvania in improving the quality of care and enriching the lives of those with bleeding disorders through education, advocacy, resource, and referral.

WPCNHF Wish List
The Chapter is always doing fundraisers to raise money for our educational programs and member support activities but sometimes we just need a few small things for the office. WPCNHF has a list of items needed in the office. If you, or anyone you know, is interested in donating any of the following please contact the office at info@westpennhemophilia.org or call us at 724-741-6160.

- White copy paper by the ream or by the case
- Colored copy paper by the ream for invitations and newsletter inserts
- Legal pads for note taking
- Sticky Notes
- Forever U.S. Postage stamps
- 10 x 13 Ready-seal envelopes for newsletter mailings
- Paper towels
- Apartment-sized refrigerator

Hemogram is published quarterly by the Western Pennsylvania Chapter of the National Hemophilia Foundation. The contents of this newsletter may be reproduced freely. The material in this newsletter is provided for your general information only. WPCNHF does not give medical advice or engage in the practice of medicine. WPCNHF under no circumstances recommends particular treatments for specific individuals, and in all cases recommends you consult your physician or local treatment center before pursuing any course of treatment.
Spotlight on the Member: Brendon Simpson
(Continued from page 9)

behalf. There have been many changes over the years and he wants to make sure that this particular population within the community continues to have access to specialists who know them as individuals. He also wants to make sure that history isn’t forgotten. He likes to keep up with what’s going on in the bleeding disorders community and feels that he can speak on behalf of others who aren’t up-to-date on changes or potential changes that could affect access to care. He’s not afraid to ask questions. He feels that if something is on his mind, chances are there are others in the community who have similar questions or concerns. He feels that others might either be afraid to ask questions or assume that someone else has already asked, so he feels it’s his responsibility to do so.

Brendon’s advice to others is to trust the doctors; however, don’t be afraid to ask questions and don’t be afraid to say you don’t understand something. He also recommends reaching out to someone who has been in your situation before. Chapter events are a good way to meet other individuals and families with bleeding disorders. Brendon also believes that if you want to do something and you have the physical capabilities to do it, you shouldn’t let your diagnosis hold you back. He says don’t be afraid to try something new. Know your limits and coordination abilities, take precautions, prepare yourself, and go for it!
Having issues with co-pays or gaps in coverage for your hemophilia A treatment?

We may be able to help.

Bayer offers a range of programs that can help you navigate insurance questions about your hemophilia A treatment. If you’re having issues with co-pays or gaps in coverage, we may be able to offer assistance. Speak with one of our case specialists to find out more.

Call 1-800-288-8374 and press 1 to speak to a trained insurance specialist!